Evidence on the efficacy of EGFR TKIs in NSCLC patients harboring uncommon EGFR mutations is limited to a few prospective studies with afatinib (LUX-lung 2, 3 and 6) [1], one prospective study with osimertinib (KCSG-LU15–09) [2], and mostly retrospective series and case reports [3,4,5]. Here, EGFR is linked to non-small cell lung carcinoma.